RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Primary Central Nervous System Lymphoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
A CSF ctDNA-based molecular panel for minimally invasive diagnosis of primary CNS lymphoma
Haoyi Li et al., Theranostics (18 October 2026)
https://doi.org/10.7150/thno.139734
- 2.
Quantitative diffusion and perfusion MRI for non-invasive MYD88/CD79B genotype characterization and prognostic stratification in primary CNS lymphoma
Xiaofang Zhou et al., Cancer Imaging (17 October 2026)
https://doi.org/10.1186/s40644-026-01145-2
- 3.
Twenty-five years survival of primary central nervous system lymphomas treated with the C5R regimen.
Blay Jean-Yves et al., European journal of cancer (Oxford, England : 1990) (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42685570/
- 4.
Corticosteroid response and biopsy decisions in tumefactive demyelination and primary central nervous system lymphoma
Xu Wang et al., Frontiers in Immunology (14 October 2026)
https://doi.org/10.3389/fimmu.2026.1988759
- 5.
Improved efficacy of Orelabrutinib plus Rituximab, Temozolomide and High-Dose Methotrexate (RMOT) vs. RMT in untreated primary CNS lymphoma: A matched analysis
Peng Zhang et al., Neuro-Oncology Advances (10 October 2026)
https://doi.org/10.1093/noajnl/vdag262
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032 · Recruiting · Phase 3 · Ono Pharmaceutical Co., Ltd.
Ages 18 and over
https://clinicaltrials.gov/study/NCT07104032
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Primary Central Nervous System Lymphoma
Primary central nervous system lymphoma is a rare cancer of the lymphatic system that starts in the brain, spinal cord, eyes or the membranes around them, without spreading from elsewhere in the body. It can cause confusion, weakness, headaches or vision problems. Treatment usually begins with high-dose methotrexate-based chemotherapy, sometimes followed by other therapies.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Primary Central Nervous System Lymphoma?
Primary central nervous system lymphoma is a rare cancer of the lymphatic system that starts in the brain, spinal cord, eyes or the membranes around them, without spreading from elsewhere in the body. It can cause confusion, weakness, headaches or vision problems. Treatment usually begins with high-dose methotrexate-based chemotherapy, sometimes followed by other therapies.
How many clinical trials are available for Primary Central Nervous System Lymphoma?
RareWays currently indexes 158 clinical trials for Primary Central Nervous System Lymphoma, of which 42 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Primary Central Nervous System Lymphoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Primary Central Nervous System Lymphoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.